Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | GMPS | P49915 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163946 | 0.88 | MAOB (0.47) | MAOBMAOABCHE | |
| SCHEMBL13338101 | 0.82 | MAOB (0.59) | MAOBMAOAGSTP1CA12CA9 | |
| SCHEMBL3759874 | 0.82 | MAOB (0.53) | MAOBMAOAGSTP1CA12CA9 | |
| SCHEMBL31103834 | 0.82 | MAOB (0.49) | MAOBMAOAGSTP1CA12CA9 | |
| SCHEMBL308414 | 0.82 | MAOB (0.49) | MAOBMAOAGSTP1CA12CA9 | |
| SCHEMBL13185268 | 0.82 | MAOB (0.49) | MAOBMAOAGSTP1CA12CA9 | |
| SCHEMBL14122832 | 0.82 | FFAR1 (0.44) | MAOBBCHECYP1A1CYP1A2 | |
| SCHEMBL13591057 | 0.81 | GSTP1 (0.42) | MAOBMAOAGSTP1CA12CA9 | |
| SCHEMBL28398195 | 0.79 | BCHE (0.53) | MAOBMAOABCHE | |
| SCHEMBL13672772 | 0.79 | MAOB (0.46) | MAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2024182772-A2 | MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-117700376-A | N-benzyl benzamide compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2024-03-15 | — | — | CN | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| US-4411912-A | Insecticidal isovaleric acid esters | ZOECON CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
| US-4243819-A | Substituted amino acids | ZOECON CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
| US-4198527-A | Ether substituted cyclopropanecarboxylic acids and esters | ZOECON CORPORATION (US) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152960-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | MAOB 585/4885MAOA 2052/4885GSTP1 1452/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | MAOB 585/4885MAOA 2052/4885GSTP1 1452/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | MAOB 3288/4885MAOA 3201/4885GSTP1 4381/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | MAOB 585/4885MAOA 2052/4885GSTP1 1452/4885 |
| US-20210309647-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | MAOB 585/4885MAOA 2052/4885GSTP1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.